A systematic review on the relation between use of statins and osteoporosis

International Journal of Pharmacology

Volumn 7, Issue 2, 2011, Pages 180-188

  Sharif, Pooneh Salari ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone formation; Bone mineral density; Osteoporosis; Statin

Indexed keywords

ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; CHOLESTEROL; CORE BINDING FACTOR; FIBROBLAST GROWTH FACTOR 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; MEVINOLIN; OSTEOCLAST DIFFERENTIATION FACTOR; SIMVASTATIN;

ARTICLE; BLOOD PRESSURE; BONE DENSITY; BONE METABOLISM; BONE REMODELING; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG ACTIVITY; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 79957830927     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2011.180.188     Document Type: Article

References (68)

1. Abdollahi, M., B. Lanjani, R. Rahimi and P. Salari, 2005. Role of oxidative stress in osteoporosis. Therapy, 2: 787-796.
2. Ahn K.S., G. Sethi, M.M. Chaturvedi and B.B. Aggarwal, 2008. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-KB ligand through modulation of NF-KB pathway. Int. I. Cancer, 123: 1733-1740.
3. Aloia, I.F., M. Li-Ng and S. Pollack, 2007. Statins and vitamin D. Am. J. Cardiol, 100: 1329-1329.
4. Bauer, D.C., G.R. Mundy, S.A. Jamal, D.M. Black and J. A. Cauley et al, 2004. Use of statins and fracture: Results of 4 prospective studies and cumulative meta¬analysis of observational studies and controlled trials. Arch. Internal Med., 164: 146-152.
5. Bjarnason, N.H., B.J. Riis and C. Christiansen, 2001. The effect of fluvastatin on parameters of bone remodeling. Osteoporos. Int., 12: 380-384.
6. Bone, H.G., D.P. Kiel, R.S. Lindsay, E.M. Lewiecki and M.A. Bolognese et al, 2007. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: A double-blind, placebo-controlled, dose-ranging trial. J. Clin. Endocrinol. Metab., 92: 4671-4677.
7. Cao, J., L. Venton, T. Sakata and B.P. Halloran, 2003. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J. Bone Miner. Res., 18: 270-277.
8. Chan, K.A., S.E. Andrade, M. Boles, D.S. Bmst and G.A. Chase et al., 2000. Inhibitors of hydroxymethyl glutaryl-coenzyme A reductase and risk of fracture among older women. Lancet, 355: 2185-2188.
9. Chan, M.H., T.W. Mak, R.W. Chiu, C.C. Chow, I. S. Chan and C.W. Lam, 2001. Simvastatin increases surem osteocalcin concentration in patients treated for hypercholesterolemia. J. Clin. Endocrinol. Metab., 86: 4556-4559.
10. Das, U.N., 2001. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot. Essent. Fatty Acids, 65: 37-40.
11. De Leo, V., G. Morgante, A. La Marca, D. Lanzetta, L. Cobellis and F. Petraglia, 2003. Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol. Endocrinol., 17: 329-332.
12. Fromihue, O., D. Modrowski and P.J. Marie, 2004. Growth factors and bone formation in osteoporosis: Roles for fibroblast growth factor and transforming growth factor beta. Curr. Pharm. Design, 10: 2593-2603.
13. Grasser, W.A., A.P. Baumann, S.F. Petras, H.J. Harwood and R. Jr. Devalaraja et al, 2003. Regulation of osteoclast differentiation by statins. J. Musculoskelet. Neuronal. Interact., 3: 53-62.
14. Gutierrez, G., I. Garrett, G. Rossini, A. Ecobedo, D. Horn and G. Mundy, 2001. Dermal application of lovastatin for 5 days stimulates bone formation in ovariectomized rats by 160%. J. Bone Miner. Res., 16: S222-S222.
15. Hamerman, D., 2005. Osteoporosis and atherosclerosis: Biological linkages and the emergence of dual-purpose therapies. Q. J. Med., 98: 467-484.
16. Horiuchi, N. and T. Maeda, 2006. Statins and bone metabolism. OralDis., 12: 85-101.
17. Ikeda, U. and K. Shimada, 1999. Statins and monocytes. Lancet, 353: 2070-2070.
18. Jadhav, S.B. and G.K. Jain, 2006. Statins and osteoporosis: New role for old drugs. J. Pharm. Pharmacol, 58: 3-18.
19. Komori, T., 2000. A fundamental transcription factor for bone and cartilage. Biochem. Biophys. Res. Commun., 276: 813-816.
20. Kong, Y.Y., H. Yoshida, I. Sarosi, H.L. Tan and E. Timms et al., 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397: 315-323.
21. Kugimiya, F., H. Kawaguchi, S. Kamekura, H. Chikuda and S. Ohba et al., 2005. Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP 6 in bone formation. J. Biol. Chem., 280: 35704-35712.
22. Lupattelli, G., A.M. Scarponi, G. Vaudo, D. Siepi and A. Roscini et al., 2004. Simvastatin increases bone mineral density in hypercholesterolemic post-menopausal women. Metabolism, 53: 744-748.
23. Maeda, T., A. Matsunuma, T. Kawane and N. Horiuchi, 2001. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun., 280: 874-877.
24. Majima, T., A. Shimatsu, Y. Komatsu, N. Satoh and A. Fukao et al., 2007a. Short-term effects of pravastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern. Med., 46: 1967-1973.
25. Majima, T., Y. Komatsu, A. Fukao, K. Ninomiya, T. Matsumura and K. Nakao, 2007b. Short term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr. J., 54: 145-151.
26. Manolagas, S.C., 2000. Birth and death of bone cells: Basic regulatory mechanism and implications for the pathogenesis and treatment of osteoporosis. Endocrinol. Rev., 21: 115-137.
27. Manolagas, S.G. and R.L. Jilka, 1995. Mechanisms of disease: Bone marrow, cytokines and bone remodeling-emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med., 332: 305-311.
28. Mathews, S.J., 2005. Biological activity of bone morphogenetic proteins (BMPs). Injury, 36: S34-S37.
29. McFarlane, S.I., R. Muniyappa, J.J. Shin, G. Bahtiyar and J.R. Sowers, 2004. Osteoporosis and cardiovascular disease: Brittle bones and boned arteries, is there a link. Endocrine, 23: 1-10.
30. Meier, C.R., R.G. Schlienger, M.E. Kraenzlin, B. Schlegel and H. Jick, 2000. HMG-CoA reductase inhibitors and the risk of fractures. JAMA, 283: 3205-3210.
31. Montagnani, A., S. Gonelli, C. Cepollaro, S. Pacini and M.S. Campagna et al., 2003. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: A 1-year longitudinal study. Bone, 23: 427-433.
32. Mundy, G., R. Garrett S. Harris, J. Chan and D. Chan. et-al, 1999. Stimulation of bone formation in vitro and in rodents by statins. Science, 286: 1946-1949.
33. Nakashima, A., R. Nakashima, T. Ito, T. Masaki and N. Yorioka, 2004. HMG-CoA reductase inhibitors prevent bone loss in patients with type 2 diabetes melhtus. Diabet. Med., 21: 1020-1024.
34. Nguyen, N.D., C.Y. Wang, J.A. Eisman and T.V. Nguyen, 2007. On the association between statin and fracture: A bayesian consideration. Bone, 40: 813-820.
35. Ohnaka, K., S. Shimoda, H. Nawata, H. Shimokawa, K. Kaibuchi, Y. Iwamoto and R. Takayanagi, 2001. Pravastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun., 287: 337-342.
36. Omoigui, S., 2005. Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med. Hypotheses, 65: 559-569.
37. Parhami, F., N. Mody, N. Gharavi, A. J. Ballard, Y. Tintut and L.L. Demer, 2002. Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. J. Bone Miner. Res., 17: 1997-2003.
38. Pasco, J.A., M.A. Kotowicz, M.J. Henry, K.M. Sanders and G.C. Nicholson, 2002. Statin use, bone mineral density and fracture risk. Arch. Intern. Med., 162: 537-540.
39. Perez-Castrillon, J.L., G. Vega, L. Abad, A. Sanz, J. Chaves, G. Hernandez and A. Duenas, 2007. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am. J. Cardiol, 99: 903-905.
40. Ray, W.A., J.R. Daugherty and M.R. Griffin, 2002. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj. Prev., 8: 276-279.
41. Reid, I.R, J. Emberson, J. Baker, A. Tonkin and D. Hunt et al, 2001. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomized controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet, 357: 509-512.
42. Reid, I.R., A. Tonkin and CP. Cannon, 2005. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial-Secondary analysis of a randomized controlled trial. Bone, 37: 190-191.
43. Rejnmark, L., N.H. Buus, P. Vestergaard, F. Andreasen, M.L. Larsen and L. Mosekilde, 2002. Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur. J. Clin. Invest, 32: 581-589.
44. Rejnmark, L., M.L. Olsen, S.P. Johnsen, P. Vestergaard, H.T. Sorensen and L. Mosekilde, 2004a. Hip fracture risk in statin users- a population-based Danish case-control study. Osteoporos. Int., 15: 452-458.
45. Rejnmark, L., N.H. Buus, P. Vestergaard, L. Heickendorff, M.L. Larsen, M.L. Larsen and L. Mosekilde, 2004b. Effects of simvastatin on bone turnover and BMD: A 1 year randomized controlled trial in postmenopausal osteopenic women. J. Bone Miner. Res., 19: 737-744.
46. Rosenson R.S., C.C. Tangney and L.C. Casey, 1999. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353: 983-984.
47. Salari P., A. Rezaie, B. Larijani and M. Abdollahi, 2008a. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med. Sci. Monitor, 14: RA37-44.
48. Salari, P., B. Larijani and M. Abdollahi, 2008b. Association of hyperhomocysteinemia with osteoporosis: A systematic review. Therapy, 5: 215-222.
49. Salari, P. and M. Abdollahi, 2009. Controversial effects of non-steroidal anti-inflammatory drugs on bone: Areview. Inflamm. Allergy Drug Targets, 8: 169-175.
50. Salari-Sharif, P. and M. Abdollahi, 2010. A systematic review on the relationship between [3-blockers and bone health. Int. J. Pharmacol., 6: 577-583.
51. Salari-Sharif, P., M. Asalforoush, F. Ameri, B. Larijani and M. Abdollahi, 2010. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: A randomized clinical trial. Age, 32: 179-186.
52. Scranton, RE., M. Young, E. Lawler, D. Solomon, D. Gagnon and J.M. Gaziano, 2005. Statin use and fracture risk: Study of a US veterans population. Arch. Internal Med., 165: 2007-2012.
53. Sirola, J., R. Honkanen, H. Kroger, J.S. Jurvelin, P. Maenpaa and S. Saarikoski, 2002. Relation of statin use and bone loss: A prospective population-based cohort study in early postmenopausal women. Osteoporos. Int., 13: 537-541.
54. Solomon, D.H., J. Avorn, C.F. Canning and P.S. Wang, 2005a. Lipid levels and bone mineral density. Am. J. Med., 118: 1414.el-1414.e5.
55. Solomon, D.H., J.S. Finkelstein, P.S. Wang and J. Avorn, 2005b. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol. Drug Saf., 14: 219-226.
56. Staal, A., J.C. Frith, M.H. French, J. Swartz and T. Gungor et al., 2003. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res., 18: 88-96.
57. Strandberg, T.E., H. Vanhanen, and M.J. Tikkanen, 1999. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet, 353: 118-119.
58. Sugiyama, M., T. Kodama, K. Konishi, K. Abe, S. Asami and S. Oikawa, 2000. Compactin and simvastatin, but not pravastatin induce bone morphogenetic protein-2 in human osteosarcoma. Biochem. Biophys. Res. Commun., 271: 688-692.
59. Tanko, L.B., Y.Z. Bagger and C. Christiansen, 2003. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif. Tissue Int., 73: 15-20.
60. Tanriverdi, H.A., A. Barut and S. Sarikaya, 2005. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol., 120: 63-68.
61. Tikiz, C, Z. Unlv, H. Tikiz, K. Ay and A. Angm et al, 2004. The effect of simvastatin on serum cytokine levels and bone metabolism in postmenopausal subjects: Negative correlation between TNF-a and anabolic bone parameters. J. Bone Miner. Metab., 22: 365-371.
62. Van Staa, T.P., S. Wegman, F. de Vries, B. Leufkens and C. Cooper, 2001. Use of statins and risk of fractures. J. Am. Med. Assoc., 285: 1850-1855.
63. Wang, P.S., D.H. Solomon, H. Mogun and J. Avorn, 2000. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. J. Am. Med. Assoc., 283: 3211-3216.
64. Wilczek, H., J. Sobra, R. Ceska, V. Justova and Z. Juzova et al, 1994. Monitoring plasma levels of vitamin D metabolites in simvastatin therapy in patients with familial hypercholesterolemia. Cas. Lek. Cesk., 133: 727-729.
65. Wilczek, H., J. Sobra, V. Justova, R. Ceska and Z. Juzova et al., 1989. Iatropathogenic effect of mevacor on vitamin D metabolism. Cas. Lek. Cesk., 128: 1254-1256.
66. Woo, J.T., T. Yonezawa, B.Y. Cha, T. Teruya and K. Nagai, 2008. Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function and survival. J. Pharmacol. Sci., 106: 547-554.
67. Yamaguchi, T., T. Sugimoto, S. Yano, M. Yamauchi and H. Sowa et al., 2002. Plasma lipids and osteoporosis in postmenopausal women. Endocrinol. J., 49: 211-217.
68. Yousefzadeh, G., B. Larijani, A. Mohammadirad, R. Heshmat and G. Dehghan et al., 2006. Determination of oxidative stress and concentration of TGF-beta 1 in the blood and saliva of osteoporotic subjects. Ann. N. Y. Acad. Sci., 1091: 142-150.